Stopped: Unavailability of Primary investigator
Analysis of embryonic cell-free DNA (cfDNA) present in the spent culture media (SCM) is a non-invasive alternative for preimplantation genetic testing for aneuploidies (PGT-A) that avoids the technical challenges and limitations of biopsy. Initial studies investigating this non-invasive PGT-A (niPGT-A) method reported variable concordance between cfDNA in SCM and the trophectoderm sample (\~ 30%-86%) and indicated a contribution from both the inner cell mass and trophectoderm to the cfDNA in SCM. This study aims to evaluate the use of the embryo culture medium as a source of genetic material for PGT-A and validate a niPGT-A protocol using cfDNA in SCM.
Age range
18 Years – 46 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
General concordance between results for cfDNA in SCM and trophectoderm biopsies
Timeframe: 4 months
Discordance per chromosome between results for cfDNA in SCM and trophectoderm biopsies
Timeframe: 4 months
Concordance per chromosome between results for cfDNA in SCM and trophectoderm
Timeframe: 4 months
Sensitivity of niPGT-A using cfDNA in SCM
Timeframe: 4 months
Specificity of niPGT-A using cfDNA in SCM
Timeframe: 4 months